The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
Open accessAbstract
Hypercholesterolemia is one of the major causes of coronary heart disease (CHD). The genes encoding the low-density lipoprotein receptor and its ligand apolipoprotein B, have been the two genes classically implicated in autosomal dominant hypercholesterolemia (ADH). Our discovery in 2003 of the first mutations of the proprotein convertase subtilisin kexin 9 gene (PCSK9) causing ADH shed light on an unknown actor in cholesterol metabolism that since then has been extensively investigated. Several PCSK9 variants have been identified, some of them are gain-of-function mutations causing hypercholesterolemia by a reduction of low-density lipoprotein (LDL) receptor levels; while others are loss-of-function variants associated with a reduction of LDL-cholesterol (LDL-C) levels and a decreased risk of CHD. In this review, we focus on reported variants, and their biological, clinical, and functional relevance. We also highlight the spectrum of hypercholesterolemia or hypobetalipoproteinemia phenotypes that are already associated with mutations in PCSK9. Finally, we present future prospects concerning this therapeutic target that might constitute a new approach to reduce cholesterol levels and CHD, and enhance the effectiveness of other lipid-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,839
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationFat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702022760507 · Cited by 747
Cited by
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 759
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Testing for an Unusual Distribution of Rare Variants
Neale, B. M., Rivas, M. A., Voight, B. F., Altshuler, D., Devlin, B., Orho-Melander, M., Kathiresan, S., Purcell, S. M., Roeder, K., & Daly, M. J. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001322 · Cited by 580
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.082 · Cited by 231
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Surdo, P. L., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., & Carfí, A. (2011) · The EMBO Reports · doi:10.1038/embor.2011.205 · Cited by 226
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah, N. G., & Prat, A. (2012) · Circulation · doi:10.1161/circulationaha.111.057406 · Cited by 212
Romagnuolo, R., Scipione, C. A., Boffa, M. B., Marcovina, S. M., Seidah, N. G., & Koschinsky, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.611988 · Cited by 206
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
“In rare cases autosomal dominant hypercholesterolemia results from point mutations of the gene encoding proprotein convertase subtilisin/kexin type-9 (PCSK9), a secreted serine protease (4).”
BackgroundMinicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V., Labbadia, G., Gabiati, C., Pigna, G., Sepe, M. L., Pannozzo, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1298 · Cited by 168
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Kasichayanula, S., Grover, A., Emery, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Gibbs, J. P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0620-7 · Cited by 135
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Pisciotta, L., Favari, E., Magnolo, L., Simonelli, S., Adorni, M. P., Sallo, R., Fancello, T., Zavaroni, I., Ardigò, D., Bernini, F., et al. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.960674 · Cited by 120
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Self-citationNi, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113035 · Cited by 107
Abifadel, M., Rabès, J.-P., Jambart, S., Halaby, G., Gannagé-Yared, M.-H., Sarkis, A., Beaino, G., Varret, M., Salem, N., Corbani, S., et al. (2009) · Human Mutation · doi:10.1002/humu.21002 · Cited by 99
Self-citationPCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Liu, M., Wu, G., Baysarowich, J., Kavana, M., Addona, G. H., Bierilo, K. K., Mudgett, J. S., Pavlovic, G., Sitlani, A., Renger, J. J., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006635 · Cited by 98
Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88
“Abifadel and coworkers identified a third candidate gene that mapped to the short arm of chromosome 1.(15) In 2003, this gene was identified as coding for PCSK9.”
BackgroundPCSK9 inhibition in the management of familial hypercholesterolemia
Ogura, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.002 · Cited by 84
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Dron, J. S., & Hegele, R. A. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000386 · Cited by 72
McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Choi, S., Aljakna, A., Srivastava, U., Peterson, B. R., Deng, B., Prat, A., & Korstanje, R. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-112 · Cited by 28
“Mutations in PCSK9 have been identified in familial autosomal dominant hypercholesterolemia patients, and gain-of-function mutations increase LDL cholesterol concentration [1,2].”
BackgroundDurairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
PCSK9 Mediates Dyslipidemia Induced by Olanzapine Treatment in Schizophrenia Patients
Huang, J., Xiao, J., Peng, Z., Shao, P., Sun, M., Long, Y., Wang, X., Shen, M., Kang, D., Yang, Y., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06042-z · Cited by 16
“As a liver-derived glycoprotein, it modulates LDL-C levels by promoting low-density lipoprotein receptor (LDLR) degradation (Abifadel et al. 2009; Lagace 2014), as it attaches to and internalizes LDLR into lysosomes, thereby promoting their destruction (Rashid et al.”
BackgroundTran-Dinh, A., Levoye, A., Lambert, G., Louedec, L., Journé, C., Meilhac, O., & Amarenco, P. (2014) · Stroke · doi:10.1161/strokeaha.114.005958 · Cited by 13
Metadata
- Authors
- Abifadel, M., Rabès, J.-P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2009-02-03
- Volume
- 30
- Issue
- 4
- Pages
- 520-529
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2028682402
- Cited by
- 256
- References
- 87
- FWCI
- 19.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.